Diffuse large B-cell lymphoma (DLBCL) account for approximately 40% of adult non-Hodgkin lymphomas. It is clinically, morphologically and genetically a heterogeneous group of tumors composed of large ...

As the world observes World Lymphoma Awareness Day on September 15th, it 39;s a timely reminder of the ongoing battle against ...

Diffuse lymphomas of B-cell origin represent a heterogeneous group of lymphoid neoplasms. The histologically aggressive subtypes of diffuse B-cell lymphomas include biologically different entities, ...

Facilitating access to treatments for diffuse large B-cell lymphoma (DLBCL) remains a top issue. There’s a need for access to treatment and a need for better drugs in diffuse large B-cell lymphoma ...

Italian investigators sought to determine if combining R-CHOP plus ibrutinib followed by ibrutinib maintenance improved PFS in treatment-naive patients aged 65 years and younger with high-risk ABC ...

At the recent American Society of Hematology annual meeting, real-world analyses examined how polatuzumab vedotin (Polivy) ...

Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase We retrospectively analyzed 38 patients with ALK-positive DLBCL treated with ...

Researchers identified genomic alterations that defined four subtypes of diffuse large B-cell lymphoma that may predict which patients will respond to treatment and have longer OS, according to study ...

You have several treatment options if you have B-cell lymphoma. Your doctor will go over the choices, including chemotherapy, radiation, and immunotherapy. Which treatment you and your doctor pick ...

Mark Hoppus revealed on a Q&A livestream that he was diagnosed with the same form of cancer that his mother previously battled.